3779-29-1 Usage
Description
Diethyl 1,1-cyclobutanedicarboxylate is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals and chemicals. It is a colorless oil with significant applications in the pharmaceutical and chemical industries due to its versatile chemical properties.
Uses
Used in Pharmaceutical Industry:
Diethyl 1,1-cyclobutanedicarboxylate is used as a pharmaceutical intermediate for the production of Carboplatin, a widely used chemotherapy drug for the treatment of various types of cancer, including testicular, ovarian, bladder, and lung cancers. It plays a vital role in the synthesis process, contributing to the development of life-saving medications.
Used in Chemical Synthesis Studies:
Diethyl cyclobutane-1,1-dicarboxylate may also be utilized in chemical synthesis studies, where it can serve as a key component in the development of new compounds and materials. Its unique structure and properties make it a valuable asset in the field of chemical research and development.
Preparation
The preparation of diethyl 1,1-cyclobutanedicarboxylate is as follows:The major product is tetraethy1 1,1,5,5-pentanetetra-carboxylate II with diethyl malonate. To eliminate this side reaction, II was independently prepared by the addition of hydrogen bromide to diethyl allylmalonate (I) and then cyclized to II by treatment with sodium ethylate. The over-all yield from I is about 50%.
Check Digit Verification of cas no
The CAS Registry Mumber 3779-29-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,7 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3779-29:
(6*3)+(5*7)+(4*7)+(3*9)+(2*2)+(1*9)=121
121 % 10 = 1
So 3779-29-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H16O4/c1-3-13-8(11)10(6-5-7-10)9(12)14-4-2/h3-7H2,1-2H3
3779-29-1Relevant articles and documents
-
Cason,Allen
, p. 1036 (1949)
-
Preparation method of 1, 1-cycloalkane dicarboxylic acid and derivatives thereof
-
Paragraph 0057-0060, (2021/05/05)
The invention discloses a preparation method of 1, 1-cycloalkane dicarboxylic acid and derivatives thereof, which at least comprises the following steps of: forming a mixed system from malonic acid or derivatives thereof, dihalogenated hydrocarbon, tert-butyl alcohol salt and a solvent in a reactor; AND according to the method, the raw material conversion rate and the product selectivity are improved, and side reactions are hardly generated.
Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups
Jiang, Yingnan,Zhang, Ke,Gao, Suyu,Wang, Guihua,Huang, Jian,Wang, Jinhui,Chen, Lixia
, (2016/07/06)
Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.